Dr. Reddy's Laboratories heads into its May 14 quarterly print with options traders suddenly far more cautious than they have been all year.
The clearest pre-earnings signal is the sharp turn in options positioning. The put/call ratio has jumped to 1.23, more than two standard deviations above its 20-day average of 0.29 — a z-score of 2.15 that places the current defensive tilt well outside normal range. For context, the PCR had been running below 0.10 for most of April and into early May; the flip toward puts over the past week is abrupt and pronounced. The 52-week high on the PCR is 1.83, so the current reading is elevated but not at its most extreme — though the speed of the move is notable.
Price action has reinforced that caution. The ADR closed at $12.46 on May 12, down 5.2% on the day and off 6% on the week. The one-month decline now runs to about 6.4%, leaving the stock trading near its weakest recent levels heading into the report.
Short interest tells a somewhat different story — more active, but not yet alarming. Estimated short interest climbed 15% in a single session on May 11 and is up nearly 12% on the week, reaching approximately 15.4 million shares. Days to cover stands at 8.6 on the official FINRA data. The borrow market remains undemanding: cost to borrow has actually eased sharply, falling roughly 32% over the past week to just 0.41%. Availability has tightened relative to the 52-week peak but short sellers face no meaningful friction in opening new positions. The ORTEX short score of 54.6 — elevated but not extreme — reflects a stock that has incrementally attracted more bearish attention over recent weeks without triggering a full short-seller conviction trade.
The analyst picture offers some offsetting support, though recent coverage is limited. HSBC upgraded the name to Buy with a target around $16.90 per ADR in June 2025, citing a more constructive view on the pipeline. Barclays has maintained an Overweight stance over multiple review cycles. Both firms see meaningful upside from current levels — though neither has refreshed their view in the past several months, and the stock has drifted lower since those calls were made. Factor scores add nuance: Dr. Reddy's ranks in the 91st percentile on dividend consistency and in the 62nd on EPS surprise history, suggesting a company that has generally delivered. The EV/EBITDA multiple has compressed slightly over the past month, down around 0.23 turns to 13.0x, reflecting the price weakness rather than any fundamental re-rating.
The May 14 print is therefore a test of whether the operational delivery that has historically supported consensus expectations can offset the macro and sector pressures that have driven the recent selloff — and whether options traders' abrupt shift toward protection proves prescient or premature.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
